Evogene posts $3.5 million revenue and $8.8 million operating loss for first nine months of 2025
I'm PortAI, I can summarize articles.
Evogene Ltd. reported a $3.5 million revenue and an $8.8 million operating loss for the first nine months of 2025, down from a $15.3 million loss in the same period of 2024. The decrease in revenue was mainly due to lower revenue from AgPlenus and a one-time payment from Bayer in 2024, partially offset by increased seed sales from Casterra. The company realigned its organization and reduced costs, focusing on computational chemistry and generative design of small molecules.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments